James Heyes has served as Chief Scientific Officer of Genevant Sciences Corporation since July 2020. Previously, he was Senior Vice President, Technology Development from Genevant’s inception in April 2018. Prior to joining Genevant, James was Vice President, Drug Delivery of Arbutus Biopharma. He brings over 20 years of experience in lipid chemistry and nucleic acid drug delivery and is an inventor of next generation lipid nanoparticle and ligand conjugate technology, with more than 20 issued and published U.S. patents in the area. James designed the lipid components enabling the first demonstration of RNA interference in primates and the advancement of 13 clinical candidates. He holds a PhD in Medicinal and Pharmaceutical Chemistry from the University of London and a BS in Chemistry from the University of Manchester.